Results 241 to 250 of about 10,366,637 (362)

Iptacopan for Immune Thrombocytopenia and Cold Agglutinin Disease: A Global Phase 2 Basket Clinical Trial

open access: yesAmerican Journal of Hematology, Volume 101, Issue 2, Page 242-254, February 2026.
ABSTRACT Iptacopan is a first‐in‐class, oral, selective inhibitor of complement factor B that has demonstrated positive efficacy across several complement‐driven diseases. Here we evaluate the efficacy and safety of iptacopan monotherapy in adult patients with primary immune thrombocytopenia (ITP) and primary cold agglutinin disease (CAD). We performed
Alexander Röth   +13 more
wiley   +1 more source

Evaluating the Risk of Collision of Seals Swimming Within Metres of Operating Tidal Turbines

open access: yesAquatic Conservation: Marine and Freshwater Ecosystems, Volume 36, Issue 2, February 2026.
ABSTRACT We used imaging sonar to continuously monitor wildlife at an operational tidal turbine in the Pentland Firth, Scotland, between May 2022 and June 2023. Of 704 detected seal tracks, 347 occurred during turbine operation and 122 of these were detected directly upstream of the rotating blades in the horizontal plane.
Jessica Montabaranom   +4 more
wiley   +1 more source

Bispecific Antibodies Versus Chimeric Antigen Receptor T‐Cell Therapy in Relapsed/Refractory Diffuse Large B‐Cell Lymphoma: A Comparative Narrative Review of Efficacy, Safety, and Accessibility

open access: yesCancer Medicine, Volume 15, Issue 2, February 2026.
ABSTRACT Introduction Diffuse large B‐cell lymphoma (DLBCL) is the most common subtype of non‐Hodgkin lymphoma, and despite advances in frontline therapies such as rituximab, cyclophosphamide, doxorubicin hydrochloride (hydroxydaunorubicin), vincristine sulfate (Oncovin), and prednisone, approximately 30%–40% of patients develop relapsed or refractory (
Dana Sofian Abou   +6 more
wiley   +1 more source

Natural Selection of a Virus-Protective FUT2 Variant Following the Transition to Agriculture. [PDF]

open access: yesMol Biol Evol
Nordgren J   +8 more
europepmc   +1 more source

T‐cell receptor–like chimeric antigen receptor T cells targeting mesothelin: A first‐in‐human dose‐escalation trial for platinum‐resistant advanced ovarian cancer

open access: yesCancer, Volume 132, Issue 3, 1 February 2026.
Abstract Background Ovarian cancer remains a formidable therapeutic challenge due to late diagnosis, high recurrence rates, and limited treatment options. Mesothelin (MSLN) is highly expressed in ovarian cancer, making it a promising target for immunotherapy.
Yiyang Shan   +7 more
wiley   +1 more source

A comparative pharmacokinetic evaluation of two aqueous progesterone 25 mg injections in healthy postmenopausal women under fasting conditions: An open‐label, balanced, randomized, two‐treatment, two‐period, two‐sequence, single‐dose, crossover bioequivalence study

open access: yesClinical Pharmacology in Drug Development, Volume 15, Issue 2, February 2026.
Abstract The growing demand for assisted reproductive technology (ART) has increased the need for effective luteal phase support. Progesterone, essential for maintaining early pregnancy, is a critical component of ART. This open‐label, balanced, randomized, two‐treatment, crossover, single‐dose study compared the bioequivalence of aqueous progesterone ...
Noopur Vyas   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy